Save information for later
Sign Up

Learn About Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)

View Main Condition: Mucopolysaccharidoses (MPS)

What is the definition of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)?

Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Because there is so much overlap between each of these three syndromes, MPS I is currently divided into the severe and attenuated types.

What are the causes of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)?

Mutations in the IDUA gene cause MPS I. The IDUA gene provides instructions for producing an enzyme that is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). GAGs were originally called mucopolysaccharides, which is where this condition gets its name. Mutations in the IDUA gene reduce or completely eliminate the function of the IDUA enzyme. The lack of IDUA enzyme activity leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS I, are called lysosomal storage disorders. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder. Researchers believe that the GAGs may also interfere with the functions of other proteins inside the lysosomes and disrupt the movement of molecules inside the cell.

How prevalent is Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)?

Severe MPS I occurs in approximately 1 in 100,000 newborns. Attenuated MPS I is less common and occurs in about 1 in 500,000 newborns.

Is Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) Local Doctors?
Paul J. Orchard
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Pediatric Hematology Oncology
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Pediatric Hematology Oncology

Center For Pediatric Blood And Marrow Transplantation - Pediatric Specialty Care Journey Clinic

2450 Riverside Ave, 
Minneapolis, MN 
Languages Spoken:
English

Paul Orchard is a Pediatric Hematologist Oncology provider in Minneapolis, MN. Dr. Orchard is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). His top areas of expertise are Adrenoleukodystrophy (ALD), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Bone Marrow Transplant, and Osteotomy.

Raymond Y. Wang
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Medical Genetics
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Medical Genetics
1201 West La Veta Avenue, 
Orange, CA 
Languages Spoken:
English

Raymond Wang is a Medical Genetics provider in Orange, California. Dr. Wang is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Pompe Disease, and Adenoidectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Medical Genetics | Pediatrics
Elite in Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
Medical Genetics | Pediatrics

Washington University

1 Childrens Pl, Suite 8116, 
Saint Louis, MO 
Languages Spoken:
English
Accepting New Patients

Patricia Dickson is a Medical Genetics specialist and a Pediatrics provider in Saint Louis, Missouri. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). Her top areas of expertise are Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 3 (MPS III, Sanfilippo Syndrome), and Mucopolysaccharidosis Type 3B (MPS IIIB, Sanfilippo Syndrome B). Dr. Dickson is currently accepting new patients.

What are the latest Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG

Summary: This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

Who are the sources who wrote this article ?

Published Date: December 01, 2012
Published By: National Institutes of Health